Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C.
Garcia-Sanz R, et al. Among authors: lopez j.
Ann Oncol. 2019 Apr 1;30(4):612-620. doi: 10.1093/annonc/mdz009.
Ann Oncol. 2019.
PMID: 30657848
Free article.
Clinical Trial.